AstraZeneca is leaving no stone unturned in its effort to make baxdrostat the first aldosterone synthase inhibitor (ASI) to get approval for hard-to-treat hypertension. The FDA has now started a ...
Outsourcer tells MPs AI is prioritizing cases as thousands of civil servants face delays Capita is banking on Microsoft Copilot to help rescue the backlog of cases it has inherited in taking over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results